Literature DB >> 28730474

Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.

Ames C Register1, Sujata Chakraborty1, Dustin J Maly2.   

Abstract

The Src family kinases (SFKs) are an important family of tyrosine kinases that are allosterically regulated by their SH2 and SH3 domains. Engagement of SFK SH2 and SH3 domains with their intramolecular ligands leads to reduced kinase activity by stabilizing an inactive ATP-binding site conformation. Disruption of these intramolecular interactions stabilizes a more active ATP-binding site conformation and restores SFK activity. Interestingly, this allosteric relationship is bidirectional in that ATP-competitive ligands that stabilize distinct active site conformations can divergently modulate the abilities of the regulatory SH2 and SH3 domains to participate in intermolecular interactions. Here, we describe a series of assays that profile the bidirectional relationship between the ATP-binding sites and regulatory domains of SFKs. These methods can be used to discover ATP-competitive inhibitors that are selective for distinct ATP-binding site conformations of SFKs and for characterizing the effects that ATP-competitive inhibitors of SFKs have on domains that are distal to their site of interaction.

Entities:  

Keywords:  Allostery; IC50; Inhibitor; Protein kinase; Regulation; SH3 domain

Mesh:

Substances:

Year:  2017        PMID: 28730474     DOI: 10.1007/978-1-4939-7154-1_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases.

Authors:  Sujata Chakraborty; Takayuki Inukai; Linglan Fang; Martin Golkowski; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

2.  Mapping the allosteric network within a SH3 domain.

Authors:  Francesca Malagrinò; Francesca Troilo; Daniela Bonetti; Angelo Toto; Stefano Gianni
Journal:  Sci Rep       Date:  2019-06-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.